The DOI matches its Crossref record; 74 of the 76 references it cites were found in a registry or an index.
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
Open accessAbstract
Objectives: To synthesise current evidence for the effects of exenatide and liraglutide on heart rate, blood pressure and body weight. Design: Meta-analysis of available data from randomised controlled trials comparing Glucagon-like peptide-1 (GLP-1) analogues with placebo, active antidiabetic drug therapy or lifestyle intervention. Participants: Patients with type 2 diabetes. Outcome measures: Weighted mean differences between trial arms for changes in heart rate, blood pressure and body weight, after a minimum of 12-week follow-up. Results: 32 trials were included. Overall, GLP-1 agonists increased the heart rate by 1.86 beats/min (bpm) (95% CI 0.85 to 2.87) versus placebo and 1.90 bpm (1.30 to 2.50) versus active control. This effect was more evident for liraglutide and exenatide long-acting release than for exenatide twice daily. GLP-1 agonists decreased systolic blood pressure by −1.79 mm Hg (−2.94 to −0.64) and −2.39 mm Hg (−3.35 to −1.42) compared to placebo and active control, respectively. Reduction in diastolic blood pressure failed to reach statistical significance (−0.54 mm Hg (−1.15 to 0.07) vs placebo and −0.50 mm Hg (−1.24 to 0.24) vs active control). Body weight decreased by −3.31 kg (−4.05 to −2.57) compared to active control, but by only −1.22 kg (−1.51 to −0.93) compared to placebo. Conclusions: GLP-1 analogues are associated with a small increase in heart rate and modest reductions in body weight and blood pressure. Mechanisms underlying the rise in heart rate require further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Its efficacy in lowering glucose levels has been established, and it has been associated with slight reductions in weight and blood pressure.6–8”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has been associated with an increase in pulse rate.7,8”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [8]
In the citing paper
“Liraglutide is known to increase heart rate with approximately 3 bpm (36)”
From Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Variance imputation for overviews of clinical trials with continuous response
Follmann, D. A., Elliott, P., Suh, I., & Cutler, J. A. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90054-q · Cited by 1,391
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Research works printed but not linked: 2
- 10.1210/jc.81.1.327 · DOI · Paper page
- 10.1185/030079907X253870 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 295
Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Endocrine Connections · doi:10.1530/ec-17-0327 · Cited by 38
Russo, G. T., Labate, A., Giandalia, A., Romeo, E. L., Villari, P., Alibrandi, A., Perdichizzi, G., & Cucinotta, D. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0163-9 · Cited by 40
Ayoub, M., Faris, C., Juranovic, T., Chela, H. K., & Daglilar, E. S. (2024) · Cancers · doi:10.3390/cancers16091625 · Cited by 38
Incretin-Based Therapy for Diabetes
Waldrop, G. E., Zhong, J., Peters, M. C., & Rajagopalan, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.058 · Cited by 38
Consoli, A., Formoso, G., BALDASSARRE, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 40
Huang, J.-H., Chen, Y.-C., Lee, T.-I., Kao, Y.-H., Chazo, T.-F., Chen, S.-A., & Chen, Y.-J. (2016) · Peptides · doi:10.1016/j.peptides.2016.02.007 · Cited by 36
Younes, S. T., Maeda, K., Sasser, J. M., & Ryan, M. J. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00486.2019 · Cited by 36
Holt, M. K., Cook, D. R., Brierley, D. I., Richards, J. E., Reimann, F. M., Gourine, A. V., Marina, N., & Trapp, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101024 · Cited by 35
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Incretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Jaarah, D., Zoubi, M. S. A., Abdelhady, G. T., Rabi, F., & Tambuwala, M. M. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211051697 · Cited by 37
Giblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.011 · Cited by 36
Holt, M. K., Llewellyn‐Smith, I. J., Reimann, F. M., Gribble, F. M., & Trapp, S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.002 · Cited by 33
Wajdlich, M. J., & Nowicki, M. P. (2024) · Scientific Reports · doi:10.1038/s41598-024-55724-z · Cited by 39
Sassoon, D., Tune, J. D., Mather, K. J., Noblet, J. N., Eagleson, M. A., Conteh, A. M., Sturek, J. T., & Goodwill, A. G. (2017) · Diabetes · doi:10.2337/db16-1206 · Cited by 35
Song, T., Jia, Y., Li, Z., Wang, F., Ren, L., & Chen, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01072-4 · Cited by 33
Corbin, K. D., Carnero, E. A., Allerton, T. D., Tillner, J., Bock, C. P., Luyet, P., Göbel, B., Hall, K. D., Parsons, S. A., Ravussin, E., et al. (2023) · Obesity · doi:10.1002/oby.23633 · Cited by 32
Gastrointestinal–Renal Axis: Role in the Regulation of Blood Pressure
Yang, J., José, P. A., & Zeng, C. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005536 · Cited by 33
Watada, H., Kaneko, S., Komatsu, M., Agner, B. F. R., Nishida, T., Ranthe, M. F., & Nakamura, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13859 · Cited by 34
Koška, J., Migrino, R. Q., Chan, K. C., Cooper-Cox, K., & Reaven, P. D. (2021) · Diabetes Care · doi:10.2337/dc20-2014 · Cited by 34
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., den Bos, I. C. P.-V., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 33
Patorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12665 · Cited by 32
Golzarand, M., Omidian, M., & Toolabi, K. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102451 · Cited by 31
Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 30
Wang, T., Wang, F., Zhou, J., Tang, H., & Giovenale, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2804 · Cited by 31
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 30
Korsatko, S., Jensen, L., Brunner, M., Sach‐Friedl, S., Tarp, M. D., Holst, A. G., Heller, S. R., & Pieber, T. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13422 · Cited by 29
Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
Cardiovascular outcomes of liraglutide in patients with type 2 diabetes
Duan, C., Wan, T.-F., Wang, Y., & Yang, Q. (2019) · Medicine · doi:10.1097/md.0000000000017860 · Cited by 28
Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
Razavi-Nematollahi, L., & Ismail‐Beigi, F. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1266-7 · Cited by 31
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 27
Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 30
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 32
Incretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli, F. S., & Shannon, R. P. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0195 · Cited by 27
Goldenberg, R., & Berard, L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1372118 · Cited by 27
Chen, W. J. Y., Diamant, M., de Boer, K., Harms, H. J., Robbers, L. F. H. J., van Rossum, A. C., Kramer, M. H. H., Lammertsma, A. A., & Knaapen, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0549-z · Cited by 27
Du, Q., Wang, Y.-J., Yang, S., Zhao, Y.-Y., & Han, P. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0164-2 · Cited by 26
Reda, R., Piccinini, F., Martinelli, G., & Carbonaro, A. (2021) · Computing · doi:10.1007/s00607-021-00988-w · Cited by 26
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes
Libianto, R., Davis, T. M. E., & Ekinci, E. I. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50472 · Cited by 26
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
Tanaka, K., Saisho, Y., Kawai, T., Tanaka, M., Meguro, S., Irie, J., Imai, T., Shigihara, T., Morimoto, J., Yajima, K., et al. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej14-0602 · Cited by 26
Clarke, S. J., McCormick, L. M., & Dutka, D. P. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-12 · Cited by 25
Incretin‐based medications for type 2 diabetes: an overview of reviews
Gamble, J., Clarke, A. M. F., Myers, K. J., Agnew, M. D., Hatch, K., Snow, M., & Davis, E. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12465 · Cited by 25
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
Al‐Sadawi, M., Aslam, F. M., Tao, M., Alsaiqali, M., Almasry, I. O., Fan, R., Rashba, E. J., & Singh, A. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101218 · Cited by 26
The role of food intake regulating peptides in cardiovascular regulation
Mikulášková, B., Maletı́nská, L., Zicha, J., & Kuneš, J. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.021 · Cited by 25
The risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
Effects of incretin-based therapy in patients with heart failure and myocardial infarction
Mikhail, N. E. (2014) · Endocrine · doi:10.1007/s12020-014-0175-4 · Cited by 22
Liraglutide in the treatment of obesity
Ng, S. Y. A., & Wilding, J. P. H. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.925870 · Cited by 26
Chiefari, E., Capula, C., Vero, A., Oliverio, R., Puccio, L., Liguori, R., Pullano, V., Greco, M., Foti, D., Tirinato, D., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0412 · Cited by 22
Devineni, D., Akbarpour, M., Gong, Y., & Wong, N. D. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07403-2 · Cited by 24
Dar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 25
Chan, C., Lin, F.-J., Chen, Y., Lin, Y., Higa, S., Chen, S.-A., & Chen, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713100 · Cited by 21
Current Perspectives on Long-term Obesity Pharmacotherapy
Wharton, S. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.07.005 · Cited by 22
Wei, W., Buysman, E. K., Grabner, M., Xie, L., Brekke, L. N., Ke, X., Chu, J. W., & LEVIN, P. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12828 · Cited by 21
Iijima, T., Shibuya, M., Ito, Y., & Terauchi, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14000 · Cited by 21
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Donner, T. W., & Joseph, J. J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50286 · Cited by 21
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
Raskin, P., & Mann, K. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s35331 · Cited by 21
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
Gurung, T., Waugh, N. R., O’Hare, J. P., & Shyangdan, D. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s34418 · Cited by 21
Self-citationJi, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 21
Finan, B., Douros, J. D., Goldwater, R., Hansen, A. M. K., Hjerpsted, J., Hjøllund, K. R., Kankam, M. K., Knerr, P. J., Konkar, A. A., Mowery, S. A., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102129 · Cited by 21
Giblett, J. P., Axell, R. G., White, P. A., Clarke, S. J., McCormick, L., Read, P. A., Reinhold, J., Brown, A. J., O’Sullivan, M., West, N. E. J., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0416-3 · Cited by 20
Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
Lorenzi, M. F., Ploug, U. J., Langer, J., Skovgaard, R., Zoratti, M. J., & Jansen, J. P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0217-4 · Cited by 20
Kitten, A., Kamath, M., Ryan, L., & Reveles, K. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221174 · Cited by 21
Glucagon-Like Peptide-1 Agonists
Stanton, E. W., Manasyan, A., Banerjee, R., Hong, K. M., Koesters, E. C., & Daar, D. A. (2024) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000004089 · Cited by 21
Liu, X., Patel, K. P., & Zheng, H. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022542 · Cited by 19
Nathanson, D., Frick, M., Ullman, B., & Nyström, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0116-2 · Cited by 19
Semantic Modelling of Smart Healthcare Data
Reda, R., Piccinini, F., & Carbonaro, A. (2018) · Advances in intelligent systems and computing · doi:10.1007/978-3-030-01057-7_32 · Cited by 19
Glucagon-Like Peptide-1 and Blood Pressure in Young and Healthy Adults from the General Population
Krisai, P., Aeschbacher, S., Schoen, T., Bossard, M., van der Stouwe, J. G., Dörig, L., Todd, J., Estis, J., Risch, M., Risch, L., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04718 · Cited by 19
Cacciatori, V., Zoppini, G., Bellavere, F., Rigolon, R., Thomaseth, K., Pichiri, I., Trombetta, M., Dauriz, M., De Santi, F., Targher, G., et al. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2017-00300 · Cited by 18
Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Oduah, M.-T. A., Sundaram, V., & Reddy, Y. N. V. (2023) · Cardiac failure review · doi:10.15420/cfr.2022.25 · Cited by 18
Rydén, A., Nyman, G. C., Nalin, L., Andréasson, S., Korsgren, O., Eriksson, O., & Jensen‐Waern, M. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.04.002 · Cited by 18
Cardiovascular and hemodynamic effects of glucagon-like peptide-1
Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 17
New Agents for the Treatment of Type 2 Diabetes
Libianto, R., & Ekinci, E. I. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.007 · Cited by 18
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 16
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.12.011 · Cited by 16
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
Demmel, V., Sandberg-Schaal, A., Jacobsen, J. B., Golor, G., Pettersson, J., & Flint, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0442-0 · Cited by 16
Cardiometabolic crosstalk in obesity-associated arterial hypertension
Jordan, J., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9348-1 · Cited by 17
Chen, Z., Hu, Y., Hu, F. B., Manson, J. E., Rimm, E. B., Doria, A., & Sun, Q. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.08.031 · Cited by 15
The new NICE guidelines for type 2 diabetes – a critical analysis
O’Hare, J. P., Millar-Jones, D., Hanif, W., Hicks, D., Evans, M., Leslie, D., Bain, S. C., & Barnett, A. H. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.006 · Cited by 15
Self-citationWysham, C., MacConell, L., & Hardy, E. (2016) · Diabetes Care · doi:10.2337/dc16-0238 · Cited by 15
Yan, L., Li, L., Peng, Y. D., Song, G., Ye, S., Du, L. Y., Hou, J. N., & Ji, Q. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0646-y · Cited by 16
Ahmadi, S., Shahsavani, M. B., Tavaf, Z., Albaghlany, R. M., Kumar, A., Moosavi‐Movahedi, A. A., & Yousefi, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266833 · Cited by 13
New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?
Jayawardene, D., Ward, G. M., O'Neal, D. N., Theverkalam, G., MacIsaac, A. I., & MacIsaac, R. J. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.05.007 · Cited by 13
Lundgren, J. R., Færch, K., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Lauritzen, T., Holst, J. J., Vistisen, D., Jørgensen, M. E., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0937-7 · Cited by 13
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · Cardiology Research · doi:10.14740/cr1459 · Cited by 14
Medical treatment of Cushing’s disease with concurrent diabetes mellitus
Mehlich, A., Bolanowski, M., Mehlich, D., & Witek, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1174119 · Cited by 13
Triplitt, C. L., & Solis‐Herrera, C. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607981 · Cited by 13
Simonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 13
Gao, L., Yu, S., Cipriani, A., Wu, S., Huang, Y., Zhang, Z., Yang, J., Sun, Y., Yang, Z., Chai, S., et al. (2019) · Aging and Disease · doi:10.14336/ad.2019.0303 · Cited by 12
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
Engeli, S., & Jordan, J. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0374-z · Cited by 12
Ross, S. A. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.973939 · Cited by 12
Akbari, A., Hadizadeh, S., & Heidary, L. (2024) · Journal of Diabetes Research · doi:10.1155/2024/3212795 · Cited by 11
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 13
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
Janani, L., Bamehr, H., Tanha, K., Mirzabeigi, P., Montazeri, H., & Tarighi, P. (2021) · Drug Research · doi:10.1055/a-1555-2797 · Cited by 11
Osonoi, T., Saito, M., Osonoi, Y., Douguchi, S., Ofuchi, K., & Katoh, M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0070 · Cited by 12
Nowrouzi‐Sohrabi, P., Soroush, N., Tabrizi, R., Shabani-Borujeni, M., Rezaei, S., Jafari, F. M., Hosseini‐Bensenjan, M., Stricker, B. H. C., van Hoek, M., & Ahmadizar, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618208 · Cited by 11
Metadata
- Authors
- Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P.
- Affiliations
- University of Warwick (GB)
- Warwick Medical School, University of Warwick, Coventry, UK
- Corresponding author
- Holt, Tim A
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013
- Volume
- 3
- Issue
- 1
- Pages
- e001986
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3563145
- OpenAlex
- W2109677274
- Cited by
- 296
- References
- 76
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 11 · 2023: 20 · 2022: 9 · 2021: 17 · 2020: 14 · 2019: 20 · 2018: 32 · 2017: 19 · 2016: 38 · 2015: 43 · 2014: 45 · 2013: 8
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Amylin Pharmaceuticals
- National Institute for Health and Care Research (CL-2010-13-005)
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- exenatide, liraglutide, GLP-1 receptor agonists, type 2 diabetes, heart rate, blood pressure, body weight, exenatide twice daily, diabetes treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
